Novel strategies for the treatment of sepsis

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

Angus, D. C., Linde-Zwirble, W. T., Lidicker, J., Clermont, G., Carcillo, J., & Pinsky, M. R. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107000-00002 · Cited by 8,503

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

Bernard, G. R., Vincent, J.-L., Laterre, P.-F., LaRosa, S. P., Dhainaut, J.-F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441001 · Cited by 6,132

HMG-1 as a Late Mediator of Endotoxin Lethality in Mice

Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., et al. (1999) · Science · doi:10.1126/science.285.5425.248 · Cited by 3,385

Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock

Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087

Shock and Tissue Injury Induced by Recombinant Human Cachectin

Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey, T. J., Zentella, A., Albert, J. D., et al. (1986) · Science · doi:10.1126/science.3764421 · Cited by 2,549

Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

Tracey, K. J., Fong, Y., Hesse, D. G., Manogue, K. R., Lee, A. T., Kuo, G. C., Lowry, S. F., & Cerami, A. (1987) · Nature · doi:10.1038/330662a0 · Cited by 2,448 · cited 1×

Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin

Beutler, B., Milsark, I. W., & Cerami, A. C. (1985) · Science · doi:10.1126/science.3895437 · Cited by 2,352

Treatment of Gram-Negative Bacteremia and Septic Shock with HA-1A Human Monoclonal Antibody against Endotoxin: A Randomized, Double-Blind, Placebo-Controlled Trial

Ziegler, E. J., Fisher, C. J., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. N. H., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199102143240701 · Cited by 1,611

High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial

Warren, B. L., Eid, A., Singer, P., Pillay, S. S., Carl, P., Novak, I., Chalupa, P., Atherstone, A., Pénzes, I., Kübler, A., et al. (2001) · JAMA · doi:10.1001/jama.286.15.1869 · Cited by 1,419

High Mobility Group 1 Protein (Hmg-1) Stimulates Proinflammatory Cytokine Synthesis in Human Monocytes

Andersson, U., Wang, H., Palmblad, K., Aveberger, A.-C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.565 · Cited by 1,401

MIF as a glucocorticoid-induced modulator of cytokine production

Calandra, T., Bernhagen, J., Metz, C. N., Spiegel, L. A., Bacher, M., Donnelly, T., Cerami, A., & Bucala, R. (1995) · Nature · doi:10.1038/377068a0 · Cited by 1,149

Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage.

Sacks, T., Moldow, C. F., Craddock, P. R., Bowers, T. K., & Jacob, H. S. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109031 · Cited by 1,103

Effect of Prolonged Methylprednisolone Therapy in Unresolving Acute Respiratory Distress Syndrome: A Randomized Controlled Trial

Meduri, G. U., Headley, A. S., Golden, E., Carson, S. J., Umberger, R. A., Kelso, T., & Tolley, E. A. (1998) · JAMA · doi:10.1001/jama.280.2.159 · Cited by 1,008

MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia

Bernhagen, J., Calandra, T., Mitchell, R. A., Martin, S. B., Tracey, K. J., Voelter, W., Manogue, K. R., Cerami, A., & Bucala, R. (1993) · Nature · doi:10.1038/365756a0 · Cited by 999

The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.

Calandra, T., Bernhagen, J., Mitchell, R. A., & Bucala, R. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.6.1895 · Cited by 985

Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.

Okusawa, S., Gelfand, J. A., Ikejima, T., Connolly, R. J., & Dinarello, C. A. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113431 · Cited by 983

Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans

Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, doubleblind, placebo-controlled, multicenter trial

Opal, S. M., Fisher, C. J., Dhainaut, J.-F. A., Vincent, J.-L., Brase, R., Lowry, S. F., Sadoff, J. C., Slotman, G. J., Levy, H., Balk, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 865

Interleukin-1 receptor antagonist reduces mortality from endotoxin shock

Ohlsson, K., Björk, P., Bergenfeldt, M., Hageman, R., & Thompson, R. C. (1990) · Nature · doi:10.1038/348550a0 · Cited by 853

Regulation of DNA-Dependent Activities by the Functional Motifs of the High-Mobility-Group Chromosomal Proteins

Bustin, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5237 · Cited by 845

The Effects of Ibuprofen on the Physiology and Survival of Patients with Sepsis

Bernard, G. R., Wheeler, A. P., Russell, J. A., Schein, R., Summer, W. R., Steinberg, K. P., Fulkerson, W. J., Wright, P. E., Christman, B. W., Dupont, W. D., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703273361303 · Cited by 837

Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M., & Ruf, W. (2002) · Science · doi:10.1126/science.1071699 · Cited by 831

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, C. J. (1994) · JAMA · doi:10.1001/jama.1994.03510470040032 · Cited by 790

Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells

Fiuza, C., Bustin, M., Talwar, S., Tropea, M., Gerstenberger, E., Shelhamer, J. H., & Suffredini, A. F. (2003) · Blood · doi:10.1182/blood-2002-05-1300 · Cited by 737

Protection from septic shock by neutralization of macrophage migration inhibitory factor

Calandra, T., Echtenacher, B., Roy, D. L., Pugin, J., Metz, C. N., Hültner, L., Heumann, D., Männel, D., Bucala, R., & Glauser, M. P. (2000) · Nature Medicine · doi:10.1038/72262 · Cited by 723

The chemotactic receptor for human C5a anaphylatoxin

Gerard, N. P., & Gerard, C. (1991) · Nature · doi:10.1038/349614a0 · Cited by 655

Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response

Mitchell, R. A., Liao, H., Chesney, J., Fingerle-Rowson, G., Baugh, J., David, J., & Bucala, R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012511599 · Cited by 622

Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation

Ulloa, L., Ochani, M., Yang, H., Tanovic, M., Halperin, D., Yang, R., Czura, C. J., Fink, M. P., & Tracey, K. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192222999 · Cited by 585

MIF regulates innate immune responses through modulation of Toll-like receptor 4

Roger, T., David, J., Glauser, M. P., & Calandra, T. (2001) · Nature · doi:10.1038/414920a · Cited by 584

Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis

Bozza, M., Satoskar, A. R., Lin, G., Lu, B., Humbles, A. A., Gerard, C., & David, J. R. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.341 · Cited by 551

HMGB1 as a Late Mediator of Lethal Systemic Inflammation

WANG, H., YANG, H., CZURA, C. J., SAMA, A. E., & TRACEY, K. J. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.10.2106117 · Cited by 490

Steroid controversy in sepsis and septic shock: A meta-analysis

Lefering, R., & Neugebauer, E. A. M. (1995) · Critical Care Medicine · doi:10.1097/00003246-199507000-00021 · Cited by 485

Prevention of lymphocyte cell death in sepsis improves survival in mice

Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Chang, K. C., Cobb, J. P., Buchman, T. G., Korsmeyer, S. J., & Karl, I. E. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14541 · Cited by 454

Protective effects of C5a blockade in sepsis

Czermak, B. J., Sarma, V., Pierson, C. L., Warner, R. L., Huber-Lang, M., Bless, N. M., Schmal, H., Friedl, H. P., & Ward, P. A. (1999) · Nature Medicine · doi:10.1038/10512 · Cited by 404

Overexpression of Bcl-2 in Transgenic Mice Decreases Apoptosis and Improves Survival in Sepsis

Hotchkiss, R. S., Swanson, P. E., Knudson, C. M., Chang, K. C., Cobb, J. P., Osborne, D. F., Zollner, K. M., Buchman, T. G., Korsmeyer, S. J., & Karl, I. E. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.7.4148 · Cited by 381

Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings

(1989) · Journal of Critical Care · doi:10.1016/0883-9441(89)90142-1 · Cited by 357

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial

Bone, R. C., Balk, R. A., Fein, A. M., Perl, T. M., Wenzel, R. P., Reines, H. D., Quenzer, R. W., Iberti, T. J., Macintyre, N., & Schein, R. M. H. (1995) · Critical Care Medicine · doi:10.1097/00003246-199506000-00003 · Cited by 350

Risk and the Efficacy of Antiinflammatory Agents: Retrospective and Confirmatory Studies of Sepsis

Eichacker, P. Q., Parent, C., Kalil, A., Esposito, C., Cui, X., Banks, S. M., Gerstenberger, E. P., Fitz, Y., Danner, R. L., & Natanson, C. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200204-302oc · Cited by 341

Protective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression

Riedemann, N. C., Neff, T. A., Guo, R.-F., Bernacki, K. D., Laudes, I. J., Sarma, J. V., Lambris, J. D., & Ward, P. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.503 · Cited by 330

HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice

Sappington, P. L., Yang, R., Yang, H., Tracey, K. J., Delude, R. L., & Fink, M. P. (2002) · Gastroenterology · doi:10.1053/gast.2002.35391 · Cited by 320

Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned

Reinhart, K., & Karzai, W. (2001) · Critical Care Medicine · doi:10.1097/00003246-200107001-00037 · Cited by 288

Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass

Fitch, J. C. K., Rollins, S., Matis, L., Alford, B., Aranki, S., Collard, C. D., Dewar, M., Elefteriades, J., Hines, R., Kopf, G., et al. (1999) · Circulation · doi:10.1161/01.cir.100.25.2499 · Cited by 281

Chemotactic and Anaphylatoxic Fragment Cleaved from the Fifth Component of Guinea Pig Complement

Shin, H. S., Snyderman, R., Friedman, E., Mellors, A., & Mayer, M. M. (1968) · Science · doi:10.1126/science.162.3851.361 · Cited by 281

Apoptosis in sepsis: a new target for therapeutic exploration

OBERHOLZER, C., OBERHOLZER, A., CLARE-SALZLER, M., & MOLDAWER, L. L. (2001) · The FASEB Journal · doi:10.1096/fj.00-058rev · Cited by 271

Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial

Dhainaut, J.-F. A., Tenaillon, A., Le Tulzo, Y., Schlemmer, B., Solet, J.-P., Wolff, M., Holzapfel, L., Zeni, F., Dreyfuss, D., Mira, J.-P., et al. (1994) · Critical Care Medicine · doi:10.1097/00003246-199411000-00005 · Cited by 269

Prolonged Methylprednisolone Treatment Suppresses Systemic Inflammation in Patients with Unresolving Acute Respiratory Distress Syndrome: Evidence for Inadequate Endogenous Glucocorticoid Secretion and Inflammation-induced Immune Cell Resistance to Glucocorticoids

Meduri, G. U., Tolley, E. A., Chrousos, G. P., & Stentz, F. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.7.2106014 · Cited by 265

L-arginine pathway in the sepsis syndrome

LORENTE, J. A., LANDÍN, L., DE PABLO, R., RENES, E., & LISTE, D. (1993) · Critical Care Medicine · doi:10.1097/00003246-199309000-00010 · Cited by 236

Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria

Calandra, T., Spiegel, L. A., Metz, C. N., & Bucala, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11383 · Cited by 235

Clinical Trials of Immunomodulatory Therapies in Severe Sepsis and Septic Shock

Vincent, J., Sun, Q., & Dubois, M. (2002) · Clinical Infectious Diseases · doi:10.1086/339549 · Cited by 228

Role of C5a in Multiorgan Failure During Sepsis

Huber-Lang, M., Sarma, V. J., Lu, K. T., McGuire, S. R., Padgaonkar, V. A., Guo, R.-F., Younkin, E. M., Kunkel, R. G., Ding, J., Erickson, R., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.2.1193 · Cited by 224

Complement-Induced Impairment of Innate Immunity During Sepsis

Huber-Lang, M. S., Younkin, E. M., Sarma, J. V., McGuire, S. R., Lu, K. T., Guo, R. F., Padgaonkar, V. A., Curnutte, J. T., Erickson, R., & Ward, P. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.6.3223 · Cited by 200

Generation of C5-Derived Lysosomal Enzyme-Releasing Activity (C5a) by Lysates of Leukocyte Lysosomes

Goldstein, I. M., & Weissmann, G. (1974) · The Journal of Immunology · doi:10.4049/jimmunol.113.5.1583 · Cited by 194

Increased C5a receptor expression in sepsis

Riedemann, N. C., Guo, R., Neff, T. A., Laudes, I. J., Keller, K. A., Sarma, V. J., Markiewski, M. M., Mastellos, D. C., Strey, C. W., Pierson, C. L., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15409 · Cited by 190

Treatment of Severe Systemic Inflammatory Response Syndrome and Sepsis With a Novel Bradykinin Antagonist, Deltibant (CP-0127)<subtitle>Results of a Randomized, Double-blind, Placebo-Controlled Trial</subtitle>

Fein, A. M. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540300050033 · Cited by 173

Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: Results from a prospective, randomized, double-blind study

Spies, C. D., Reinhart, K., Witt, I., Meier-Hellmann, A., Hannemann, L., Bredle, D. L., & Schaffartzik, W. (1994) · Critical Care Medicine · doi:10.1097/00003246-199411000-00007 · Cited by 170

Immunotherapy of sepsis

van der Poll, T. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00093-7 · Cited by 167

A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome

YU, M., & TOMASA, G. (1993) · Critical Care Medicine · doi:10.1097/00003246-199311000-00010 · Cited by 158

Increased C5a receptor expression in sepsis

Riedemann, N. C., Guo, R., Neff, T. A., Laudes, I. J., Keller, K. A., Sarma, V. J., Markiewski, M. M., Mastellos, D. C., Strey, C. W., Pierson, C. L., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215409 · Cited by 157

Cytokines IL-1 β, IL-6, and TNF- α Enhance In Vitro Growth of Bacteria

MEDURI, G. U., KANANGAT, S., STEFAN, J., TOLLEY, E., & SCHABERG, D. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.160.3.9807080 · Cited by 155

Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial

Dhainaut, J.-F., Tenaillon, A., Hemmer, M., Damas, P., Tulzo, Y. L., Radermacher, P., Schaller, M., Sollet, J.-P., Wolff, M., Holzapfel, L., et al. (1998) · Critical Care Medicine · doi:10.1097/00003246-199812000-00021 · Cited by 153

Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis

Guo, R., Huber-Lang, M. S., Wang, X., Sarma, V. J., Padgaonkar, V. A., Craig, R. A., Riedemann, N. C., McClintock, S. D., Hlaing, T., Shi, M. M., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10793 · Cited by 152

Effect of Pentoxifylline in Severe Sepsis

Staubach, K.-H., Schröder, J., Stuber, F. E., Gehrke, K., Traumann, E., & Zabel, P. (1998) · Archives of Surgery · doi:10.1001/archsurg.133.1.94 · Cited by 144

Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide.

Warren, H. S., Amato, S. F., Fitting, C., Black, K. M., Loiselle, P. M., Pasternack, M. S., & Cavaillon, J. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.1.89 · Cited by 128

Migration-Inhibitory Factor Gene-Deficient Mice Are Susceptible to CutaneousLeishmania majorInfection

Satoskar, A. R., Bozza, M. T., Rodríguez‐Sosa, M., Lin, G., & David, J. R. (2001) · Infection and Immunity · doi:10.1128/iai.69.2.906-911.2001 · Cited by 127

Prolonged inhibition of nitric oxide synthesis in severe septic shock: A clinical study

Avontuur, J. A. M., Nolthenius, R. P. T., van Bodegom, J. W., & Bruining, H. A. (1998) · Critical Care Medicine · doi:10.1097/00003246-199804000-00012 · Cited by 120

Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium

Koebernick, H., Grode, L., David, J. R., Rohde, W., Rolph, M. S., Mittrücker, H., & Kaufmann, S. H. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212488699 · Cited by 118

Effects of cytokines and endotoxin on the intracellular growth of bacteria

Kanangat, S., Meduri, G. U., Tolley, E. A., Patterson, D. R., Meduri, C. U., Pak, C., Griffin, J. P., Bronze, M. S., & Schaberg, D. R. (1999) · Infection and Immunity · doi:10.1128/iai.67.6.2834-2840.1999 · Cited by 110

Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis

Lehmann, L. E., Novender, U., Schroeder, S., Pietsch, T., von Spiegel, T., Putensen, C., Hoeft, A., & Stüber, F. (2001) · Intensive Care Medicine · doi:10.1007/s001340101022 · Cited by 106

Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock

Zéni, F., Pain, P., Vindimian, M., Gay, J.-P., Géry, P., Bertrand, M., Page, Y., Page, D., Vermesch, R., & Bertrand, J.-C. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00005 · Cited by 87

C5a receptor and thymocyte apoptosis in sepsis

Riedemann, N. C., Guo, R., Laudes, I. J., Keller, K. A., Sarma, V. J., Padgaonkar, V. A., Zetoune, F. S., & Ward, P. A. (2002) · The FASEB Journal · doi:10.1096/fj.02-0033fje · Cited by 86

Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme

Cohen, J. (1999) · British Medical Bulletin · doi:10.1258/0007142991902222 · Cited by 71

The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculaturein vitro andin vivo

Schumacher, W. A., Fantone, J. C., Kunkel, S. L., Webb, R. C., & Lucchesi, B. R. (1991) · Inflammation Research · doi:10.1007/bf01988727 · Cited by 68

A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetase

Schilling, J., Cakmakci, M., Bättig, U., & Geroulanos, S. (1993) · Intensive Care Medicine · doi:10.1007/bf01694775 · Cited by 67

Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome

Gando, S., Nishihira, J., Kobayashi, S., Morimoto, Y., Nanzaki, S., & Kemmotsu, O. (2001) · Intensive Care Medicine · doi:10.1007/s001340000818 · Cited by 60

New and Emerging Therapies for Sepsis

Healy, D. P. (2002) · Annals of Pharmacotherapy · doi:10.1345/aph.1a283 · Cited by 46

Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis

Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., Metz, C., Miller, E. J., et al. (2004) · Nature Medicine · doi:10.1038/nm1124 · Cited by 1,170

Reversing established sepsis with antagonists of endogenous high-mobility group box 1

Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434651100 · Cited by 1,126

Acute chorioamnionitis and funisitis: definition, pathologic features, and clinical significance

Kim, C. J., Romero, R., Chaemsaithong, P., Chaiyasit, N., Yoon, B. H., & Kim, Y. M. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.08.040 · Cited by 910

ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity

Matsuzawa, A., Saegusa, K., Noguchi, T., Sadamitsu, C., Nishitoh, H., Nagai, S., Koyasu, S., Matsumoto, K., Takeda, K., & Ichijo, H. (2005) · Nature Immunology · doi:10.1038/ni1200 · Cited by 667

Dopamine mediates vagal modulation of the immune system by electroacupuncture

Torres-Rosas, R., Yehia, G., Peña, G., Mishra, P., del Rocio Thompson-Bonilla, M., Moreno-Eutimio, M. A., Arriaga-Pizano, L. A., Isibasi, A., & Ulloa, L. (2014) · Nature Medicine · doi:10.1038/nm.3479 · Cited by 630